Elena Prokupets Biography and Net Worth

Director of C4 Therapeutics

The estimated Net Worth of Elena Prokupets is at least $5.32 Million dollars as of 29 July 2021. Elena Prokupets owns over 15,593 units of C4 Therapeutics stock worth over $4,613,549 and over the last few years Elena sold CCCC stock worth over $701,841.

Elena has made over 1 trades of the C4 Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Elena sold 15,593 units of CCCC stock worth $701,841 on 29 July 2021.

The largest trade Elena's ever made was selling 15,593 units of C4 Therapeutics stock on 29 July 2021 worth over $701,841. On average, Elena trades about 3,898 units every 0 days since 2020. As of 29 July 2021 Elena still owns at least 102,981 units of C4 Therapeutics stock.

How do I contact Elena Prokupets?: The corporate mailing address for Prokupets and other C4 Therapeutics executives is , , . C4 Therapeutics can also be reached via phone at 617-231-0700 and via email at [email protected]. Learn More on Elena Prokupets' contact information.
Has Elena Prokupets been buying or selling shares of C4 Therapeutics?: Elena Prokupets has not been actively trading shares of C4 Therapeutics during the past quarter. Most recently, Elena Prokupets sold 1,850 shares of the business's stock in a transaction on Monday, September 27th. The shares were sold at an average price of $50.04, for a transaction totalling $92,574.00. Learn More on Elena Prokupets' trading history.
Who are C4 Therapeutics' active insiders?: C4 Therapeutics' insider roster includes Adam Crystal (Insider), Stewart Fisher (Insider), Elena Prokupets (Director), Malcolm Salter (Director), and Jolie Siegel (Insider). Learn More on C4 Therapeutics' active insiders.

Elena Prokupets Insider Trading History at C4 Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/27/2021	Sell	1,850	$50.04	$92,574.00
9/23/2021	Sell	19,180	$50.41	$966,863.80
9/21/2021	Sell	10,321	$50.14	$517,494.94
9/17/2021	Sell	10,840	$50.05	$542,542.00
9/15/2021	Sell	54,193	$48.82	$2,645,702.26
9/13/2021	Sell	6,660	$50.07	$333,466.20
9/10/2021	Sell	2,550	$50.00	$127,500.00
8/2/2021	Sell	4,257	$45.01	$191,607.57
7/29/2021	Sell	11,336	$45.00	$510,120.00

Elena Prokupets Buying and Selling Activity at C4 Therapeutics

C4 Therapeutics Company Overview

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $3.93

$3.92

$4.07

50 Day Range

MA: $5.77

$4.05

$7.00

2 Week Range

Now: $3.93

$1.06

$11.88

Volume

51,470 shs

Average Volume

2,104,867 shs

Market Capitalization

$277.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.04

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

From Colonial Metals | Ad

Claim your FREE 2024 Gold Guide